Cerebrolysin (Brain Peptides Complex)

1 ml of injection contains:

active substance:

cerebrolysin concentrate (a complex of peptides obtained from the pig brain) 215.2 mg,

excipients :

sodium hydroxide;

water for injections

Cerebrolysin has a positive effect on cognitive impairment, on the processes of memorization.

• chronic cerebrovascular insufficiency;
• ischemic stroke;
• Alzheimer's disease;
• dementia syndrome of various origins;
• traumatic injuries of the brain and spinal cord;
• mental retardation in children;
• hyperactivity and attention deficit disorder in children;
• in complex therapy for endogenous depression resistant to antidepressants.

With caution, the drug is prescribed in the first trimester of pregnancy and during lactation.

During pregnancy and during breastfeeding, Cerebrolysin should be used only after a thorough analysis of the ratio of the positive effect of treatment and the risk associated with its implementation.

The results of experimental studies do not give reason to believe that Cerebrolysin has a teratogenic effect or has a toxic effect on the fetus.

However, no similar clinical studies have been conducted.

• acute renal failure;
• individual intolerance to the drug;
• epileptic status.

From the digestive tract: rarely - loss of appetite, dyspepsia, diarrhea, constipation, nausea and vomiting.

From the side of the central nervous system and peripheral nervous system: in rare cases, the expected effect of activation was accompanied by excitation (manifested aggressive behavior, confusion, insomnia). There are reports of occurrence in isolated cases (

On the part of the immune system: extremely rarely - hypersensitivity reactions or allergic reactions, manifested by headache, pain in the neck, limbs, lower back, shortness of breath, chills and collapse state.

Reaction to the introduction: with excessively fast administration in rare cases, a sensation of fever, sweating, dizziness is possible; in isolated cases - palpitations or arrhythmias. Therefore, the drug should be administered slowly.

Local reactions: rarely - redness of the skin, itching and burning at the injection site.

Other: extremely rare - cases of hyperventilation, arterial hypertension, arterial hypotension, fatigue, tremor, depression, apathy, dizziness, and flu-like symptoms (cough, runny nose, respiratory tract infections) were reported according to research results.

It should be noted that some undesirable effects (agitation, arterial hypertension, arterial hypotension, lethargy, tremor, depression, apathy, dizziness, headache, shortness of breath, diarrhea, nausea) were detected during clinical trials and occurred equally in patients receiving Cerebrolysin, and in patients of the placebo group.

Given the pharmacological profile of the drug, Cerebrolysin should pay particular attention to possible additive effects when used together with antidepressants, including MAO inhibitors. In such cases, it is recommended to reduce the dose of antidepressant.

Cerebrolysin and balanced amino acid solutions should not be mixed in the same infusion solution.

Cerebrolysin is incompatible with solutions that include lipids and with solutions that change the pH of the medium (5–8).

Intramuscularly (up to 5 ml), intravenously (up to 10 ml), intravenously, by slow infusion (from 10 to 50 ml).

Doses and duration of treatment depend on the nature and severity of the disease, as well as on the age of the patient. It is possible to prescribe single doses, the value of which can reach 50 ml, however, it is more preferable to conduct a course of treatment. The recommended optimal course of treatment is daily injections for 10–20 days.

Acute conditions (ischemic stroke, head injury, complications after neurosurgical operations) - from 10 to 50 ml.

The residual period of stroke and traumatic damage to the brain and spinal cord is from 5 to 50 ml.

Psycho-organic syndrome and depression - from 5 to 30 ml.

Alzheimer's disease, dementia of vascular and combined Alzheimer's-vascular origin - from 5 to 30 ml.

In neuropediatric practice - 0.1-0.2 ml / kg.

To increase the effectiveness of treatment, repeated courses can be carried out until an improvement in the patient's condition due to treatment is observed. After the first course, the frequency of administration of doses can be reduced to 2 or 3 times a week.

Doses of 10 to 50 ml are recommended to be administered only by slow intravenous infusion after dilution with the proposed standard solutions for infusion. The duration of infusion is from 15 to 60 minutes.

Checked and confirmed the compatibility of the drug (within 24 hours at room temperature and the presence of lighting) with the following standard solutions for infusion:

- 0.9% sodium chloride solution (9 mg NaCl / ml);

- Ringer's solution (Na + - 153.98 mmol / L; Ca2 + - 2.74 mmol / L; K + - 4.02 mmol / L; Cl− - 163.48 mmol / L).

- 5% glucose solution.

The simultaneous administration of the drug Cerebrolysin with vitamins and drugs that improve cardiac circulation is allowed, however, these drugs should not be mixed in the same syringe with the drug Cerebrolysin. Use only a clear solution and only once.

Influence on the ability to drive vehicles and work with mechanisms. Clinical trials have shown that cerebrolysin does not affect the ability to drive vehicles and use mechanisms.

Injection